Gotham Asset Management LLC Takes $264,000 Position in 10x Genomics, Inc. (NASDAQ:TXG)

Gotham Asset Management LLC acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 18,389 shares of the company’s stock, valued at approximately $264,000.

Several other institutional investors have also modified their holdings of the business. Signaturefd LLC raised its position in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after buying an additional 1,452 shares during the last quarter. Blue Trust Inc. raised its position in 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after buying an additional 1,299 shares during the last quarter. Sound Income Strategies LLC raised its position in 10x Genomics by 65.2% in the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after buying an additional 1,330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in 10x Genomics in the 4th quarter valued at approximately $52,000. Finally, SRS Capital Advisors Inc. raised its position in 10x Genomics by 817.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock valued at $70,000 after buying an additional 4,324 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Price Performance

TXG opened at $9.08 on Wednesday. The business has a fifty day simple moving average of $8.72 and a 200 day simple moving average of $12.23. The company has a market capitalization of $1.11 billion, a PE ratio of -5.97 and a beta of 1.94. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $24.85.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. The business had revenue of $154.88 million during the quarter, compared to the consensus estimate of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The firm’s quarterly revenue was down 2.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.50) EPS. Equities analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Serge Saxonov sold 5,092 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the sale, the chief executive officer now directly owns 879,482 shares in the company, valued at approximately $9,735,865.74. This represents a 0.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Alan Mateo acquired 40,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were acquired at an average price of $11.14 per share, with a total value of $445,600.00. Following the completion of the transaction, the director now owns 61,691 shares in the company, valued at $687,237.74. The trade was a 184.41% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 9.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TXG shares. The Goldman Sachs Group lowered their price target on 10x Genomics from $7.50 to $6.50 and set a “sell” rating on the stock in a research report on Monday, May 12th. Canaccord Genuity Group lowered their price target on 10x Genomics from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, May 12th. Morgan Stanley lowered their price target on 10x Genomics from $26.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday. Citigroup lowered their price target on 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Finally, Leerink Partnrs lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $15.81.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.